On August 28, 2015, the FDA issued a safety warning for a newer type of type 2 diabetes medication known as DPP-4 inhibitors or gliptins.
There have been reports that these medications can cause severe and possibly disabling joint pain.
Which medications contain gliptins (DPP-4 inhibitors)?
- Januvia (sitagliptin)
- Onglyza (saxagliptin)
- Tradjenta (linagliptin)
- Nesina (alogliptin)
- Janumet and Janumet XR (metformin and sitagliptin)
- Kombiglyze XR (saxagliptin and metformin)
- Glyxambi (empagliflozin and linagliptin)
- Jentadueto (metformin and linagliptin)
- Kazano (alogliptin and metformin)
- Oseni (alogliptin and pioglitazone)
Why was a FDA safety warning issued for gliptin medications?
The FDA issued the warning due to continued reports of severe joint pain associated with the use of gliptin medications. See More